Moderna – BiotechReality – Information Intelligence System for Biopharma

Moderna Reports Q1 2025 Results: Revenue Dips, Focus Shifts to Oncology Amid Expense Cuts

By Ajmal Aseem
4 May 2025

Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst [Read More…]

News Healthcare & Pharmaceuticals

Moderna succeeds in mRNA flu shot after phase 3 trials; seeking approval

By Editor's Desk
14 September 2023

Moderna’s new mRNA (messenger Ribonucleic Acid) flu shot completed the phase 3 trials with succeeding data. They are aiming to launch in early 2024. The flu vaccine – mRNA-1010 has produced an immune response against all four A and B strains – A/H1N1, A/H3N2, influenza B/Yamagata, and B/Victoria.

Tag: Moderna

Moderna Reports Q1 2025 Results: Revenue Dips, Focus Shifts to Oncology Amid Expense Cuts

Moderna succeeds in mRNA flu shot after phase 3 trials; seeking approval

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment